• Je něco špatně v tomto záznamu ?

Myelodysplastic syndromes

edited by Ota Fuchs

Publikováno
Rijeka : InTech, 2016
Vydání
First published
Stránkování
200 stran : ilustrace; 24 cm

Jazyk angličtina Země Chorvatsko

Typ dokumentu kolektivní monografie

Perzistentní odkaz   https://www.medvik.cz/link/MED00194796

This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. Nakladatelská anotace

Další formy díla

Dostupný též online

Vlastník Detaily Služby
ÚHKT ÚHKT Signatura K1086 [1]
Ročník/svazek Lokace Signatura Stav Objednat
000      
00000nam a2200000 i 4500
001      
MED00194796
003      
CZ-PrNML
005      
20210304101039.0
008      
180328s2016 ci a e 000 0|eng||
009      
BK
020    __
$a 978-953-51-2586-0 $q (vázáno)
020    __
$a 978-953-51-2587-7 $q (online)
024    7_
$a 10.5772/61879 $2 doi
040    __
$a ABA008 $b cze $d ABA008 $e rda
041    0_
$a eng
044    __
$a ci
072    _7
$a 616 $x Patologie. Klinická medicína $2 Konspekt $9 14 $7 sk136316
245    00
$a Myelodysplastic syndromes / $c edited by Ota Fuchs
250    __
$a First published
264    _1
$a Rijeka : $b InTech, $c 2016
300    __
$a 200 stran : $b ilustrace; $c 24 cm
336    __
$a text $b txt $2 rdacontent
337    __
$a bez média $b n $2 rdamedia
338    __
$a svazek $b nc $2 rdacarrier
520    __
$a This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. Nakladatelská anotace
530    __
$a Dostupný též online
650    07
$a hematologie a transfuzní lékařství $7 nlk20040147649 $2 mednas
650    07
$a hematologie $7 D006405 $2 czmesh
650    07
$a myelodysplastické syndromy $7 D009190 $2 czmesh
655    _4
$a kolektivní monografie $7 nlk-pt178
700    1_
$a Fuchs, Ota $7 xx0060631 $4 edt
856    41
$u https://kramerius.medvik.cz/search/handle/uuid:MED00194796-54dfc948-2dc2-4cef-ab41-8756acc9d84b $y digitalizovaný dokument
856    41
$u https://www.intechopen.com/books/myelodysplastic-syndromes $y plný text volně přístupný
910    __
$a ABC011 $b K1086 $y 1
990    __
$a 20180328130202 $b ABA008
991    __
$a 20210304101033 $b ABA008
999    __
$a ok $b medvik21 $g 1285884 $s 208958

Hledat články